Consensus OncoCyte Corporation

Equities

OCX

US68235C2061

Market Closed - Nasdaq 04:30:01 2024-03-27 pm EDT 5-day change 1st Jan Change
2.98 USD -0.60% Intraday chart for OncoCyte Corporation -2.93% +19.20%

Evolution of the average Target Price on OncoCyte Corporation

Price target over the last 5 years

History of analyst recommendation changes

ac55b6871b1f6eb.rkt7ZwigbM0GG6CMftrUWooT6pZeM3tt9EG5GKBy7fU.1jwqAEXFLaY_fM_UF7_jN_t_3Mkaf0pVnSbzU9k6qrLeGhALQfIvo0xy5Q~e3a46e6e0488a4fbd96ea7501e2435e5
Needham Adjusts Price Target on OncoCyte to $3.60 From $4.25, Maintains Buy Rating MT
Benchmark Adjusts Price Target on OncoCyte to $5 From $9, Maintains Speculative Buy Rating MT
Piper Sandler Adjusts Price Target on OncoCyte to $3.50 From $6, Keeps Neutral Rating MT
Needham Adjusts OncoCyte's Price Target to $4.25 From $9, Keeps Buy Rating MT
Needham Trims Price Target on OncoCyte to $0.45 From $1.40, Keeps Buy Rating MT
Lake Street Downgrades Oncocyte to Hold From Buy, Cuts Price Target to $0.50 From $3 MT
Piper Sandler Downgrades OncoCyte to Neutral From Overweight, Adjusts Price Target to $0.50 From $1 MT
Piper Sandler Trims Price Target on OncoCyte to $1 From $1.50, Maintains Overweight Rating MT
Lake Street Adjusts OncoCyte Price Target to $3 From $6, Maintains Buy Rating MT
Needham Trims OncoCyte's Price Target to $2.10 From $2.25 on 'Lower Revenue Estimates;' Buy Rating Kept MT
Stephens Downgrades OncoCyte to Equalweight From Overweight, Adjusts Price Target to $1.25 From $2 MT
Piper Sandler Trims OncoCyte's Price Target to $1.40 From $1.80, Maintains Overweight Rating MT
Needham Adjusts OncoCyte's Price Target to $2.25 From $4 on 'Peer Multiple Compression,' Reiterates Buy Rating MT
Piper Sandler Adjusts OncoCyte's Price Target to $1.80 from $3.10, Keeps Overweight Rating MT
KeyBanc Downgrades OncoCyte to Sector Weight From Overweight, Citing Need for Added Capital, Removes $7 Price Target MT
Lake Street Adjusts OncoCyte Price Target to $6 From $11, Maintains Buy Rating MT
Needham Adjusts OncoCyte's Price Target to $4 From $5, Citing Peer Multiple Compression; Buy Rating Kept MT
Stephens Initiates OncoCyte With Overweight Rating, $3.10 Price Target MT
Stephens Starts OncoCyte at Overweight With $3.10 Price Target MT
Needham Lowers OncoCyte's Price Target to $5 From $7, Maintains Buy Rating MT
Needham Cuts OncoCyte's Price Target to $7 From $8 on Lower Revenue Estimates; Buy Rating Kept MT
ONCOCYTE : Chardan Suspends Coverage on OncoCyte at Neutral Rating With $2 Price Target MT
ONCOCYTE : Needham Assumes OncoCyte at Buy with $8 Price Target MT
ONCOCYTE : Piper Sandler Upgrades OncoCyte to Overweight From Neutral, Adjusts Price Target to $4 From $2 MT
ONCOCYTE : BTIG Starts OncoCyte at Buy With $5 Price Target MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
4
Last Close Price
2.98 USD
Average target price
3.533 USD
Spread / Average Target
+18.57%
High Price Target
4 USD
Spread / Highest target
+34.23%
Low Price Target
3 USD
Spread / Lowest Target
+0.67%

Consensus detail

Consensus revision (last 18 months)

Analysts covering OncoCyte Corporation

Needham & Co.
Benchmark Company
Piper Sandler
Lake Street
Stephens Inc.
KeyBanc Capital Markets
Chardan
Trading Rating
Investor Rating
ESG Refinitiv
D+
More Ratings